Tilray Brands (TLRY) Total Non-Current Liabilities (2019 - 2026)
Tilray Brands' (TLRY) quarterly Total Non-Current Liabilities came in at $728.7 million in Q2 2026, up 27.91% YoY from $569.8 million in Q2 2025, and up 32.75% on a QoQ basis from $549.0 million in Q1 2026.
Tilray Brands (TLRY) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 8 years of Total Non-Current Liabilities data on file, last reported at $728.7 million in Q2 2026.
- Quarterly Total Non-Current Liabilities rose 27.91% year-over-year to $728.7 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $728.7 million (up 27.91% YoY) and the FY2026 annual result came in at $728.7 million, up 27.91% from the prior year.
- Total Non-Current Liabilities climbed to $728.7 million in Q2 2026, from $549.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q1 2022 to a low of $549.0 million in Q1 2026.
- A 5-year average of $831.5 million and a median of $855.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 35.52% — and 2026, when it climbed 27.91%.
- Tracing TLRY's Total Non-Current Liabilities over 5 years: stood at $991.0 million in 2022, then declined by 6.74% to $924.2 million in 2023, then declined by 20.13% to $738.1 million in 2024, then declined by 25.26% to $551.7 million in 2025, then surged by 32.1% to $728.7 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $728.7 million (Q2 2026), $549.0 million (Q1 2026), and $551.7 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 334.00 Mn |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn | 728.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 728.75 Mn |
| Feb 28, 2026 | 548.95 Mn |
| Nov 30, 2025 | 551.67 Mn |
| Aug 31, 2025 | 561.99 Mn |
| May 31, 2025 | 569.75 Mn |
| Nov 30, 2024 | 738.13 Mn |
| Aug 31, 2024 | 778.35 Mn |
| May 31, 2024 | 778.40 Mn |
| Feb 29, 2024 | 855.82 Mn |
| Nov 30, 2023 | 924.20 Mn |
| Aug 31, 2023 | 987.69 Mn |
| May 31, 2023 | 966.43 Mn |
| Feb 28, 2023 | 958.53 Mn |
| Nov 30, 2022 | 991.05 Mn |
| Aug 31, 2022 | 1.03 Bn |
| May 31, 2022 | 1.01 Bn |
| Feb 28, 2022 | 1.16 Bn |
| Nov 30, 2021 | 1.29 Bn |
| Aug 31, 2021 | 1.60 Bn |
| May 31, 2021 | 1.56 Bn |